Management of Elevated Free PSA

Initial Risk Assessment

The European Association of Urology recommends evaluating PSA level, digital rectal examination (DRE), life expectancy, family history, and ethnicity as part of the initial risk assessment 1
Patients with PSA values above 4.0 ng/ml should be referred to urology due to increased risk of prostate cancer 2
Significant PSA velocity changes (≥1.0 ng/ml/year) should prompt referral, even if absolute PSA is within normal range 2

The European Urology guidelines suggest confirming elevated PSA with a repeat test under standardized conditions before considering further testing 1
Calculate PSA density (PSA-D; serum PSA divided by prostate volume) as it is one of the strongest predictors for clinically significant prostate cancer (csPCa), especially with a cut-off of 0.15 ng/ml/cc 1
Order multiparametric MRI (mpMRI) as it has high sensitivity (91% for ISUP grade 2 cancers) and can reduce unnecessary biopsies 1

For patients with PI-RADS 4-5 lesions and PSA-D >0.20 ng/ml, proceed with targeted biopsy plus perilesional sampling 1

Men who have <15 years of life expectancy are unlikely to benefit from early diagnosis 1
Breaking the compulsory link between diagnosis and active treatment is the only way to decrease overtreatment risk while maintaining potential benefit of early diagnosis 1

The American Urological Association was not mentioned, however, treatment depends on Gleason score, clinical stage, patient's age, overall health, and preferences 3
Options include radical prostatectomy (for localized disease), radiation therapy, active surveillance (for low-risk cancers), and androgen deprivation therapy (for advanced disease) 3

Regular PSA monitoring is essential after definitive treatment 3
After radical prostatectomy, biochemical recurrence is defined as PSA ≥0.2 ng/ml with a confirmatory value 3